omniture
logo
Search
ONWARD THERAPEUTICS SA
Media Room

Latest News

rss

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Ther...

2024-01-24 15:00 1453

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy

EPALINGES, Switzerland and MONTPELLIER, France, June 20, 2022 /PRNewswire/ -- Onward Therapeutics S...

2022-06-20 12:00 1920

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier

EPALINGES, Switzerland, June 8, 2021 /PRNewswire/ -- Onward Therapeutics (Onward) and Institut du C...

2021-06-08 12:00 1328

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

LAUSANNE, Switzerland, Feb. 17, 2021 /PRNewswire/ -- Onward Therapeutics SA (Onward) announced toda...

2021-02-17 13:00 1529

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

Onward Also Makes an Equity Investment in Biomunex LAUSANNE, Switzerland, Feb. 16, 2021 /PRNewswi...

2021-02-16 13:00 1934